Research progress of Bub1 in cancers

Abstract

Wang Mengni, Lyu Weiguo. Research progress of Bub1 in cancers[J]. Journal of International Oncology, 2020, 47(5): 289-292.

References33

[1]	Overlack K, Primorac I, Vleugel M, et al. A molecular basis for the differential roles of Bub1 and BubR1 in the spindle assembly checkpoint[J]. Elife, 2015,4:e05269. DOI: 10.7554/eLife.05269. doi:10.7554/eLife.05269pmid:25611342
[2]	Edwards F, Maton G, Gareil N, et al. Bub-1 promotes amphitelic chromosome biorientation via multiple activities at the kinetochore[J]. Elife, 2018,7:e40690. DOI: 10.7554/ eLife.40690. doi:10.7554/eLife.40690pmid:30547880
[3]	Moyle MW, Kim T, Hattersley N, et al. A Bub1-Mad1 interaction targets the Mad1-Mad2 complex to unattached kinetochores to initiate the spindle checkpoint[J]. J Cell Biol, 2014,204(5):647-657. DOI: 10.1083/jcb.201311015. doi:10.1083/jcb.201311015pmid:24567362
[4]	Zhang G, Kruse T, Lopez-Mendez B, et al. Bub1 positions Mad1 close to KNL1 MELT repeats to promote checkpoint signalling[J]. Nat Commun, 2017,8:15822. DOI: 10.1038/ncomms15822. doi:10.1038/ncomms15822pmid:28604727
[5]	Leontiou I, London N, May KM, et al. The Bub1-TPR domain interacts directly with Mad3 to generate robust spindle checkpoint arrest[J]. Curr Biol, 2019, 29(14): 2407- 2414. e7. DOI: 10.1016/j.cub.2019.06.011
[6]	Akera T, Trimm E, Lampson MA. Molecular strategies of meiotic cheating by selfish centromeres[J]. Cell, 2019, 178(5): 1132- 1144. e10. DOI: 10.1016/j.cell.2019.07.001.
[7]	Limzerwala JF, van Deursen JM. Crystallizing BubR1's kinase activity[J]. Cell Res, 2019,29(8):605-606. DOI: 10.1038/s41422-019-0199-7. doi:10.1038/s41422-019-0199-7pmid:31253942
[8]	Hindriksen S, Lens SMA, Hadders MA. The ins and outs of Aurora B inner centromere localization[J]. Front Cell Dev Biol, 2017,5:112. DOI: 10.3389/fcell.2017.00112. doi:10.3389/fcell.2017.00112pmid:29312936
[9]	Zhang M, Liang C, Chen Q, et al. Histone H2A phosphorylation recruits topoisomerase Ⅱ alpha to centromeres to safeguard genomic stability[J]. EMBO J, 2020,39(3):e101863. DOI: 10.15252/embj.2019101863. doi:10.15252/embj.2019101863pmid:31769059
[10]	Li F, Kim H, Ji Z, et al. The Bub3-Bub1 complex promotes telomere DNA replication[J]. Mol Cell, 2018,70(3): 395-407.e4. DOI: 10.1016/j.molcel.2018.03.032. doi:10.1016/j.molcel.2018.03.032pmid:29727616
[11]	Nyati S, Schinske-Sebolt K, Pitchiaya S, et al. The kinase activity of the Ser/Thr kinase Bub1 promotes TGF-β signaling[J]. Sci Signal, 2015,8(358): ra1. DOI: 10.1126 /scisignal.2005379 . doi:10.1126/scisignal.aaa4696pmid:25564676
[12]	Lang F, Sun Z, Pei Y, et al. Shugoshin 1 is dislocated by KSHV-encoded LANA inducing aneuploidy[J]. PLoS Pathog, 2018,14(9):e1007253. DOI: 10.1371/journal.ppat.1007253. doi:10.1371/journal.ppat.1007253pmid:30212568
[13]	Sun Z, Jha HC, Robertson ES. Bub1 in complex with LANA recruits PCNA to regulate Kaposi's sarcoma-associated herpesvirus latent replication and DNA translesion synjournal[J]. J Virol, 2015,89(20):10206-10218. DOI: 10.1128/JVI.01524-15. doi:10.1128/JVI.01524-15pmid:26223641
[14]	Yang S, Yu J, Fan Z, et al. Bub1 facilitates virus entry through endocytosis in a model of drosophila pathogenesis[J]. J Virol, 2018,92(18).pii:e00254-18. DOI: 10.1128/JVI.00254-18. doi:10.1128/JVI.00254-18pmid:29976667
[15]	Arai E, Gotoh M, Tian Y, et al. Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas[J]. Int J Cancer, 2015,137(11):2589-2606. DOI: 10.1002/ijc.29630. doi:10.1002/ijc.29630pmid:26061684
[16]	Zhang W, Gao L, Wang C, et al. Combining bioinformatics and experiments to idenjpgy and verify key genes with prognostic values in endometrial carcinoma[J]. J Cancer, 2020,11(3):716-732. DOI: 10.7150/jca.35854. doi:10.7150/jca.35854pmid:31942195
[17]	Davidson B, Nymoen DA, Elgaaen BV, et al. Bub1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma[J]. Virchows Arch, 2014,464(6):701-707. DOI: 10.1007/s00428-014-1577-7. doi:10.1007/s00428-014-1577-7
[18]	Sun Q, Zhao H, Zhang C, et al. Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers[J]. Oncotarget, 2017,8(26):42983-42996. DOI: 10.18632/oncotarget.17785. doi:10.18632/oncotarget.17785pmid:28562334
[19]	Wang Z, Katsaros D, Shen Y, et al. Biological and clinical significance of MAD2L1 and Bub1, genes frequently appearing in expression signatures for breast cancer prognosis[J]. PLoS One, 2015,10(8):e0136246. DOI: 10.1371/journal.pone.0136246. doi:10.1371/journal.pone.0136246pmid:26287798
[20]	Han JY, Han YK, Park GY, et al. Bub1 is required for maintaining cancer stem cells in breast cancer cell lines[J]. Sci Rep, 2015,5:15993. DOI: 10.1038/srep15993. doi:10.1038/srep15993pmid:26522589
[21]	Qin S, Long X, Zhao Q, et al. Co-expression network analysis idenjpgied genes associated with cancer stem cell characteristics in lung squamous cell carcinoma[J]. Cancer Invest, 2020,38(1):13-22. DOI: 10.1080/07357907.2019.1697281. doi:10.1080/07357907.2019.1697281pmid:31770041
[22]	Xu B, Xu T, Liu H, et al. MiR-490-5p suppresses cell proliferation and invasion by targeting Bub1 in hepatocellular carcinoma cells[J]. Pharmacology, 2017,100(5-6):269-282. DOI: 10.1159/000477667. doi:10.1159/000477667pmid:28810242
[23]	Saurin AT. Kinase and phosphatase cross-talk at the kinetochore[J]. Front Cell Dev Biol, 2018,6:62. DOI: 10.33 89/fcell.2018.00062. doi:10.3389/fcell.2018.00062pmid:29971233
[24]	Pagotto S, Veronese A, Soranno A, et al. HNRNPL restrains miR-155 targeting of Bub1 to stabilize aberrant karyotypes of transformed cells in chronic lymphocytic leukemia[J]. Cancers (Basel), 2019,11(4).pii:575. DOI: 10.3390/cancers11040575. doi:10.3390/cancers11040575
[25]	de Voer RM, Geurts van Kessel A, Weren RD, et al. Germline mutations in the spindle assembly checkpoint genes Bub1 and Bub3 are risk factors for colorectal cancer[J]. Gastroenterology, 2013,145(3):544-547. DOI: 10.1053/j.gastro.2013.06.001. doi:10.1053/j.gastro.2013.06.001
[26]	Vargas-Parra GM, González-Acosta M, Thompson BA, et al. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis[J]. Int J Cancer, 2017,141(7):1365-1380. DOI: 10.1002/ijc.30820. doi:10.1002/ijc.30820pmid:28577310
[27]	Mukherjee A, Joseph C, Craze M, et al. The role of Bub and CDC proteins in low-grade breast cancers[J]. Lancet, 2015,385:S72. DOI: 10.1016/S0140-6736(15)60387-7. doi:10.1016/S0140-6736(15)60387-7pmid:26312894
[28]	Hou SQ, Ouyang M, Brandmaier A, et al. PTEN in the maintenance of genome integrity: from DNA replication to chromosome segregation[J]. Bioessays, 2017,39(10):e1700082. DOI: 10.1002/bies.201700082.
[29]	Pussila M, Toronen P, Einarsdottir E, et al. Mlh1 deficiency in normal mouse colon mucosa associates with chromosomally unstable colon cancer[J]. Carcinogenesis, 2018,39(6):788-797. DOI: 10.1093/carcin/bgy056. doi:10.1093/carcin/bgy056pmid:29701748
[30]	Austria T, Marion C, Yu V, et al. Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways[J]. Int J Cancer, 2018,143(11):2932-2942. DOI: 10.1002/ijc.31659. doi:10.1002/ijc.31659pmid:29978915
[31]	Martinez R, Blasina A, Hallin JF, et al. Mitotic checkpoint kinase Mps1 has a role in normal physiology which impacts clinical utility[J]. PLoS One, 2015,10(9):e0138616. DOI: 10.1371/journal.pone.0138616. doi:10.1371/journal.pone.0138616pmid:26398286
[32]	Baron AP, von Schubert C, Cubizolles F,, et al. Probing the cataly-tic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524[J]. Elife 2016,5.pii:e12187. DOI: 10.7554/eLife.12187. doi:10.7554/eLife.12187pmid:26885717
[33]	Siemeister G, Mengel A, Fernandez-Montalvan AE, et al. Inhibition of Bub1 kinase by BAY 1816032 sensitizes tumor cells toward Taxanes, ATR, and PARP inhibitors in vitro and in vivo[J]. Clin Cancer Res, 2019,25(4):1404-1414. DOI: 10.1158/1078-0432.CCR-18-0628. doi:10.1158/1078-0432.CCR-18-0628pmid:30429199

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References33

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.